Pages that link to "Q41102726"
Jump to navigation
Jump to search
The following pages link to Correlation between severity and SMN protein level in spinal muscular atrophy (Q41102726):
Displaying 50 items.
- Restoration of full-length SMN promoted by adenoviral vectors expressing RNA antisense oligonucleotides embedded in U7 snRNAs (Q21142695) (← links)
- Alternative splicing events are a late feature of pathology in a mouse model of spinal muscular atrophy (Q21144988) (← links)
- WRAP53 is essential for Cajal body formation and for targeting the survival of motor neuron complex to Cajal bodies (Q21145787) (← links)
- Molecular and therapeutic potential and toxicity of valproic acid (Q21296867) (← links)
- SMA CARNIVAL TRIAL PART II: a prospective, single-armed trial of L-carnitine and valproic acid in ambulatory children with spinal muscular atrophy (Q21560963) (← links)
- SMA CARNI-VAL trial part I: double-blind, randomized, placebo-controlled trial of L-carnitine and valproic acid in spinal muscular atrophy (Q21562176) (← links)
- Modeling spinal muscular atrophy in Drosophila (Q21562542) (← links)
- Survival Motor Neuron Protein Regulates Stem Cell Division, Proliferation, and Differentiation in Drosophila (Q21563387) (← links)
- A novel function for SMN, the spinal muscular atrophy disease gene product, in pre-mRNA splicing (Q22008514) (← links)
- Gemin3: A novel DEAD box protein that interacts with SMN, the spinal muscular atrophy gene product, and is a component of gems (Q22010941) (← links)
- CAJAL BODIES: A Long History of Discovery (Q22065410) (← links)
- Coiled Bodies and Gems: Janus or Gemini? (Q22066143) (← links)
- Gemin4. A novel component of the SMN complex that is found in both gems and nucleoli (Q22253358) (← links)
- Drug treatment for spinal muscular atrophy types II and III (Q24200270) (← links)
- Drug treatment for spinal muscular atrophy type I (Q24200377) (← links)
- Drug treatment for spinal muscular atrophy types II and III (Q24234414) (← links)
- Drug treatment for spinal muscular atrophy type I (Q24234523) (← links)
- Drug treatment for spinal muscular atrophy type I (Q24241017) (← links)
- Drug treatment for spinal muscular atrophy types II and III (Q24241759) (← links)
- Drug treatment for spinal muscular atrophy types II and III (Q24244639) (← links)
- Drug treatment for spinal muscular atrophy type I (Q24244774) (← links)
- Spinal muscular atrophy disrupts the interaction of ZPR1 with the SMN protein (Q24291073) (← links)
- The Gemin5 protein of the SMN complex identifies snRNAs (Q24297645) (← links)
- The splicing regulator Sam68 binds to a novel exonic splicing silencer and functions in SMN2 alternative splicing in spinal muscular atrophy (Q24301061) (← links)
- The zinc finger protein ZPR1 is a potential modifier of spinal muscular atrophy. (Q24307665) (← links)
- Coupled in vitro import of U snRNPs and SMN, the spinal muscular atrophy protein (Q24307701) (← links)
- Identification of a candidate modifying gene for spinal muscular atrophy by comparative genomics (Q24311585) (← links)
- The spinal muscular atrophy disease gene product, SMN, and its associated protein SIP1 are in a complex with spliceosomal snRNP proteins (Q24316085) (← links)
- The SMN-SIP1 complex has an essential role in spliceosomal snRNP biogenesis (Q24316121) (← links)
- ZPR1 is essential for survival and is required for localization of the survival motor neurons (SMN) protein to Cajal bodies (Q24519083) (← links)
- SMN interacts with a novel family of hnRNP and spliceosomal proteins (Q24535803) (← links)
- Intragenic telSMN mutations: frequency, distribution, evidence of a founder effect, and modification of the spinal muscular atrophy phenotype by cenSMN copy number. (Q24539804) (← links)
- Symmetrical dimethylation of arginine residues in spliceosomal Sm protein B/B' and the Sm-like protein LSm4, and their interaction with the SMN protein. (Q24540057) (← links)
- SMN transcript levels in leukocytes of SMA patients determined by absolute real-time PCR (Q24599124) (← links)
- Coilin forms the bridge between Cajal bodies and SMN, the spinal muscular atrophy protein (Q24600358) (← links)
- The contribution of mouse models to understanding the pathogenesis of spinal muscular atrophy (Q24604444) (← links)
- Indoprofen upregulates the survival motor neuron protein through a cyclooxygenase-independent mechanism (Q24613087) (← links)
- Heterogeneity of subcellular localization and electrophoretic mobility of survival motor neuron (SMN) protein in mammalian neural cells and tissues (Q24651106) (← links)
- A SMN missense mutation complements SMN2 restoring snRNPs and rescuing SMA mice (Q24657021) (← links)
- A functional interaction between the survival motor neuron complex and RNA polymerase II (Q24674951) (← links)
- Opening the window: The case for carrier and perinatal screening for spinal muscular atrophy (Q26741506) (← links)
- Copy Number Variations in the Survival Motor Neuron Genes: Implications for Spinal Muscular Atrophy and Other Neurodegenerative Diseases (Q26750803) (← links)
- Molecular Mechanisms of Neurodegeneration in Spinal Muscular Atrophy (Q26752798) (← links)
- Homeostatic plasticity at the Drosophila neuromuscular junction (Q26829672) (← links)
- iPSC-Based Models to Unravel Key Pathogenetic Processes Underlying Motor Neuron Disease Development (Q26863612) (← links)
- Applicability of histone deacetylase inhibition for the treatment of spinal muscular atrophy (Q26864605) (← links)
- Stem Cell Transplantation for Motor Neuron Disease: Current Approaches and Future Perspectives (Q26995278) (← links)
- Splicing therapy for neuromuscular disease (Q27009581) (← links)
- Skeletal muscle DNA damage precedes spinal motor neuron DNA damage in a mouse model of Spinal Muscular Atrophy (SMA) (Q27312220) (← links)
- Genetic correction of human induced pluripotent stem cells from patients with spinal muscular atrophy (Q27328843) (← links)